Enhancing sepsis biomarker development: key considerations from public and private perspectives

Area of Science:

• Critical care medicine
• Biomarker research
• Translational science

Background:

• Sepsis biomarker implementation in emergency settings faces significant hurdles.
• A public-private workshop convened experts to address these challenges in sepsis biomarker development and clinical integration.

Purpose of the Study:

• Identify obstacles in sepsis biomarker research and clinical translation.
• Outline critical path milestones for biomarker development.
• Discuss novel strategies for biomarker discovery and implementation in sepsis.

Main Methods:

• Expert consensus and discussion from a 3-day public-private workshop.
• Analysis of current barriers including diagnostic performance, validation, cost, and education.
• Exploration of emerging technologies like artificial intelligence and time-resolved testing.

Main Results:

• Key barriers identified: lack of consensus on diagnostic performance, absence of development recommendations, cost/resource issues, validation challenges, and limited awareness.
• Promising biomarker-guided interventions (e.g., sTREM-1, Adrenomedullin) require further evaluation.
• Artificial intelligence shows potential for analyzing complex sepsis data and identifying patient endotypes.

Conclusions:

• Sepsis biomarker development necessitates a comprehensive, multidisciplinary strategy.
• Collaboration between scientific and commercial entities is crucial.
• Expedited regulatory approval processes are needed to facilitate clinical adoption.